Prior exposure to thalidomides is associated with TP53 mutations in t-MDS/AML, and treatment with lenalidomide in vitro and in vivo provides a selective advantage to Trp53-mutant hematopoietic stem and progenitor cells providing a possible mechanistic reasoning for this increased incidence [21]. Here, TP53 is linked to acute myeloid leukemia.